Verona Pharma PLC ADR (VRNA)

Currency in USD
105.190
-0.050(-0.05%)
Closed·
105.040-0.150(-0.14%)
·
VRNA Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
VRNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
105.190105.360
52 wk Range
24.500105.500
Key Statistics
Prev. Close
105.24
Open
105.28
Day's Range
105.19-105.36
52 wk Range
24.5-105.5
Volume
1.97M
Average Volume (3m)
3.45M
1-Year Change
326.22%
Book Value / Share
3.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VRNA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
106.222
Upside
+0.98%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Verona Pharma PLC ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Verona Pharma PLC ADR Company Profile

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Verona Pharma PLC ADR Earnings Call Summary for Q4/2024

  • Q4 2024 EPS of -$0.05 beat -$0.07 forecast; revenue of $35.65M exceeded $6.14M estimate
  • Stock surged 5.98% post-earnings; 254.66% return over past year
  • O2VARE therapy adoption strong with 4,600+ healthcare providers prescribing
  • $400M cash reserves; aiming for cash flow breakeven at $250-300M annual revenue
  • Preparing for European and global regulatory expansion; sustained net losses remain a challenge
Last Updated: 27/02/2025, 16:14
Read Full Transcript

Compare VRNA to Peers and Sector

Metrics to compare
VRNA
Peers
Sector
Relationship
P/E Ratio
−111.7x−1.2x−0.5x
PEG Ratio
−3.120.000.00
Price/Book
32.6x−0.1x2.6x
Price / LTM Sales
40.9x1.8x3.3x
Upside (Analyst Target)
1.7%121.4%41.6%
Fair Value Upside
Unlock24.3%5.9%Unlock

Analyst Ratings

1 Buy
10 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 106.222
(+0.98% Upside)

Earnings

Latest Release
Aug 13, 2025
EPS / Forecast
0.14 / 0.029
Revenue / Forecast
103.14M / 95.37M
EPS Revisions
Last 90 days

VRNA Income Statement

People Also Watch

62.44
BMNR
+5.87%
163.21
CRCL
+1.27%
192.00
ALAB
+7.01%
74.95
MP
+3.11%
122.00
INSM
+8.07%

FAQ

What Stock Exchange Does Verona Pharma ADR Trade On?

Verona Pharma ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Verona Pharma ADR?

The stock symbol for Verona Pharma ADR is "VRNA."

What Is the Verona Pharma ADR Market Cap?

As of today, Verona Pharma ADR market cap is 9.07B.

What Is Verona Pharma ADR's Earnings Per Share (TTM)?

The Verona Pharma ADR EPS (TTM) is -0.97.

When Is the Next Verona Pharma ADR Earnings Date?

Verona Pharma ADR will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is VRNA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Verona Pharma ADR Stock Split?

Verona Pharma ADR has split 0 times.

How Many Employees Does Verona Pharma ADR Have?

Verona Pharma ADR has 209 employees.

What is the current trading status of Verona Pharma ADR (VRNA)?

As of 13 Aug 2025, Verona Pharma ADR (VRNA) is trading at a price of 105.19, with a previous close of 105.24. The stock has fluctuated within a day range of 105.19 to 105.36, while its 52-week range spans from 24.50 to 105.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.